Prospective randomized, group-controlled pilot study 2021-2022 of clinical causality, efficacy and safety of the CE-marked app mediteo m+
Phase 4
- Conditions
- Drug Adherence
- Registration Number
- DRKS00026278
- Lead Sponsor
- Mediteo GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 87
Inclusion Criteria
Chronic medication
Exclusion Criteria
Serious internal, neurological, vision disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Actual tablet count divided by target tablet count
- Secondary Outcome Measures
Name Time Method Blood pressure